Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. - Publikation

Publikation

Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial.

Wissenschaftlicher Artikel/Review - 07.09.2023

Schmidt Marcus, Nitz Ulrike A, Reimer Toralf, Schmatloch Sabine, Graf Heiko, Just Marianne, Stickeler Elmar, Untch Michael, Runnebaum Ingo B, Belau Antje, Huober Jens, Jackisch Christian, Hofmann Manfred, Krocker Jutta, Nekljudova Valentina, Loibl Sibylle, GBG/AGO-B, NOGGO/WSG study groups

Zitation

Schmidt M, Nitz U, Reimer T, Schmatloch S, Graf H, Just M, Stickeler E, Untch M, Runnebaum I, Belau A, Huober J, Jackisch C, Hofmann M, Krocker J, Nekljudova V, Loibl S, GBG/AGO-B, NOGGO/WSG study groups. Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trial. Eur J Cancer 2023; 194:113324.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur J Cancer 2023; 194

Veröffentlichungsdatum

07.09.2023

eISSN (Online)

1879-0852

Seiten

113324

Kurzbeschreibung/Zielsetzung

Evaluation of the impact of a de-escaleted chemotherapy regimen consisting of capecitabine (Cap) on invasive disease-free survival (iDFS) in patients ≥65 years with node-positive/high-risk node-negative early breast cancer (BC) receiving ibandronate (Ib).